{"id":90820,"date":"2024-06-26T12:10:49","date_gmt":"2024-06-26T17:10:49","guid":{"rendered":"https:\/\/pulmonx.com\/about-pulmonx\/"},"modified":"2025-01-29T07:49:40","modified_gmt":"2025-01-29T12:49:40","slug":"about-pulmonx","status":"publish","type":"page","link":"https:\/\/pulmonx.com\/uk-en\/about-pulmonx\/","title":{"rendered":"About Pulmonx"},"content":{"rendered":"\n
\n
\n
\n
\n <\/div>\n <\/div>\n <\/div>\n
\n
\n
\n \n
\n
\n

A Global Leader in Interventional Pulmonology, Planning Tools, and Treatments for Obstructive Lung Disease<\/h1>\n

Based in Redwood City, California, and Neuch\u00e2tel, Switzerland, Pulmonx is the maker of the Zephyr\u00ae<\/sup> Valve. The Zephyr Valve was granted breakthrough status and approved by the FDA in June 2018, because according to the FDA it \u201crepresents a breakthrough technology as the device offers bronchoscopic lung volume reduction without surgery and its associated risks. This device offers a significant, clinically meaningful advantage over the current standard of care and therefore, its availability is also in the best interest of patients.\u201d20<\/sup><\/a><\/p>\n

The company\u2019s commercially available portfolio includes the Zephyr Valve. More than 100 scientific articles have been published on the clinical benefits of Zephyr Valves, including multiple meta-analyses, review articles, cost-effectiveness analyses and risk-benefit analyses. It also includes:<\/p>\n <\/div>\n<\/div>\n <\/div>\n <\/div>\n <\/div>\n

\n
\n
\n \n
\n
\n \"COPD-Technology-Zephyr-Valve\" \n <\/div>\n \n \n <\/div>\n\n
\n
\n

The Zephyr Valve<\/h2>\n

The Zephyr Endobronchial Valve is an implantable device used to occlude all airways feeding the hyperinflated lobe of a lung that is most diseased with emphysema.<\/p> <\/div>\n<\/div>\n

\n
\n <\/div>\n <\/div>\n <\/div>\n
\n \n
\n
\n \"Print\" \n <\/div>\n \n \n <\/div>\n\n
\n
\n

StratX\u00ae<\/sup> Lung Analysis Reports<\/h2>\n

A cloud-based quantitative computed tomography (CT) analysis service that provides information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the Zephyr Valve treatment.<\/p> <\/div>\n<\/div>\n <\/div>\n

\n \n
\n
\n \"Chartis-Tablet-Pulmonx-Technology\" \n <\/div>\n \n \n <\/div>\n\n
\n
\n

The Chartis\u00ae<\/sup> Pulmonary Assessment System<\/h2>\n

A proprietary balloon catheter and console provides precise flow and pressure readings for specific lobes in the lung to assess absence of collateral ventilation.<\/p> <\/div>\n<\/div>\n <\/div>\n <\/div>\n <\/div>\n

\n
\n
\n
\n
\n \n
\n
\n

This combination of assessment tools and therapeutics enables physicians to successfully predict outcomes and provide optimal treatment for each individual patient.<\/strong><\/h4> <\/div>\n<\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n
\n
\n
\n \n
\n
\n

Meeting an Unmet Need<\/strong><\/h2>\n

COPD refers to a group of lung diseases characterized by obstruction of airflow that interferes with normal breathing.<\/p> <\/div>\n<\/div>\n

\n
\n \n
\n
\n